Average Bioequivalence with Expanding Limits (ABEL)

Performs comparative bioavailability calculations for Average Bioequivalence with Expanding Limits (ABEL). Implemented are 'Method A' and 'Method B' and the detection of outliers. If the design allows, assessment of the empiric Type I Error and iteratively adjusting alpha to control the consumer risk. Average Bioequivalence - optionally with a tighter (narrow therapeutic index drugs) or wider acceptance range (Gulf Cooperation Council, South Africa: Cmax) - is implemented as well.


Reference manual

It appears you don't have a PDF plugin for this browser. You can click here to download the reference manual.


1.1.0 by Helmut Schütz, 7 months ago


Report a bug at https://github.com/Helmut01/replicateBE/issues

Browse source code at https://github.com/cran/replicateBE

Authors: Helmut Schütz [aut, cre] , Michael Tomashevskiy [ctb] , Detlew Labes [ctb]

Documentation:   PDF Manual  

Task views: Clinical Trial Design, Monitoring, and Analysis

GPL (>= 3) license

Imports readxl, PowerTOST, lmerTest, nlme, pbkrtest, graphics, grDevices

Suggests knitr, rmarkdown, testthat, devtools

See at CRAN